Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer?

被引：7
|
作者：
Watanabe, Satomi [1 ]
Hayashi, Hidetoshi [1 ]
Nakagawa, Kazuhiko [1 ]
机构：
[1] Kindai Univ, Fac Med, Dept Med Oncol, 377-2 Ohno Higashi, Osaka, Osaka 5898511, Japan
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2016年 / 4卷 / 11期
关键词：
FACTOR RECEPTOR GENE; OPEN-LABEL; 1ST-LINE TREATMENT; RADIATION-THERAPY; PHASE-III; GEFITINIB; CHEMOTHERAPY; ADENOCARCINOMA; ERLOTINIB;
D O I：
10.21037/atm.2016.05.48
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Osimertinib for the treatment of patients with EGFR mutation-positive non-small cell lung cancer
    Alsharedi, M.
    Bukamur, H.
    Elhamdani, A.
    [J]. DRUGS OF TODAY, 2018, 54 (06) : 369 - 379
  • [2] Nivolumab for Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Yoshida, H.
    Kim, Y. H.
    Ozasa, H.
    Nagai, H.
    Sakamori, Y.
    Tsuji, T.
    Nomizo, T.
    Funazo, T.
    Yasuda, Y.
    Hirai, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2416 - S2416
  • [3] Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Lilenbaum, Rogerio A.
    Horn, Leora A.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (5.5): : 672 - 674
  • [4] Afatinib in EGFR mutation positive advanced non-small cell lung cancer
    Davies, R. S.
    Brewster, A. E.
    Button, M. R.
    Lester, J. F.
    [J]. LUNG CANCER, 2016, 91 : S22 - S22
  • [5] Osimertinib for treating Patients with EGFR Mutation-Positive non-small cell Lung Cancer
    Meinrenken, Susanne
    [J]. PNEUMOLOGIE, 2018, 72 (04): : 246 - 246
  • [6] AFATINIB FOR THE TREATMENT OF PATIENTS WITH EGFR-POSITIVE NON-SMALL CELL LUNG CANCER
    Bowles, D. W.
    Weickhardt, A.
    Jimeno, A.
    [J]. DRUGS OF TODAY, 2013, 49 (09) : 523 - 535
  • [7] Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer
    Park, Keunchil
    Bennouna, Jaafar
    Boyer, Michael
    Hida, Toyoaki
    Hirsh, Vera
    Kato, Terufumi
    Lug, Shun
    Mok, Tony
    Nakagawa, Kazuhiko
    O'Byrne, Kenneth
    Paz-Ares, Luis
    Schuler, Martin
    Sibilotru, Denis Moro
    Tan, Eng-Huat
    Tanaka, Hiroshi
    We, Yi-Long
    Yang, James C-H
    Zhang, Li
    Zhou, Caicun
    Maerten, Angela
    Tang, Wenbo
    Yamamoto, Nobuyuki
    [J]. LUNG CANCER, 2019, 132 : 126 - 131
  • [8] Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
    Kazuo Tamura
    Toshihiro Nukiwa
    Akihiko Gemma
    Nobuyuki Yamamoto
    Masaya Mizushima
    Kaori Ochai
    Rie Ikeda
    Hisaya Azuma
    Yoichi Nakanishi
    [J]. International Journal of Clinical Oncology, 2019, 24 : 917 - 926
  • [9] Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib
    Tamura, Kazuo
    Nukiwa, Toshihiro
    Gemma, Akihiko
    Yamamoto, Nobuyuki
    Mizushima, Masaya
    Ochai, Kaori
    Ikeda, Rie
    Azuma, Hisaya
    Nakanishi, Yoichi
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2019, 24 (08) : 917 - 926
  • [10] Efficacy of afatinib following osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
    Tamura, Tomohiro
    Okubo, Hatsumi
    Yamada, Yutaka
    Kikkawa, Yasuko
    Yamaguchi, Shozaburo
    Hashimoto, Ikuta
    Kaburagi, Takayuki
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S335 - S335
12345